Marshall Edwards announced the publication of results from its Phase 2 trial of IV phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer. The study showed that the combination of IV phenoxodiol with cisplatin was well tolerated and resulted in an overall response rate of 19% (3 out of 16) among ovarian cancer patients previously resistant to platinum. Response rate in this study was defined as the percentage of patients whose tumor demonstrated a radiologically confirmed reduction or disappearance after treatment.
Phenoxodiol is a NADH oxidase inhibitor.
For more information call (858) 792-6300 or visit www.marshalledwardsinc.com.